Latest publications

Transfused Red Blood Cell Characteristics and Kidney Transplant Outcomes Among Patients Receiving Early Posttransplant Transfusion

AbstractImportance: Red blood cell transfusion (RBCT) is frequently required in the early post-kidney transplant...

Posted by : Dr. Dewi VERNEREY
Journal name : JAMA Netw Open

Efficacy and Tolerance of Carboplatin plus Cetuximab (Simplified EXTREME Regimen) in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

AbstractAims: The EXTREME regimen is the standard for recurrent and/or metastatic head and neck squamous cell...

Posted by : Dr. Dewi VERNEREY
Journal name : Clin Oncol (R Coll Radiol)

Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82)

AbstractBackground: Several cancer immunotherapies that target the PD-L1/PD-1 pathway show promising clinical...

Posted by : Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Journal name : BMC Cancer

DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching study

AbstractTriplet DCF (docetaxel, cisplatin and 5-flurouracil) and doublet CP/CF (carboplatin and paclitaxel/cisplatin and...

Posted by : Dr. Dewi VERNEREY
Journal name : Exp Hematol Oncol

Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma

AbstractPurpose: The optimal neoadjuvant treatment for resectable carcinoma of the thoracic esophagus (TE) or...

Posted by : Dr. Dewi VERNEREY
Journal name : J Clin Oncol .

Circulating tumour DNA at baseline for individualised prognostication in patients with chemotherapy-naïve metastatic colorectal cancer. An AGEO prospective study

AbstractPurpose: Baseline circulating tumour DNA (ctDNA) is a potential prognostic marker in metastatic colorectal...

Posted by : Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Journal name : Eur J Cancer

État des lieux des pratiques de prise en charge des cancers des voies biliaires en France : résultats de l'enquête nationale ACABi

AbstractOverview of biliary tract cancer management practices in France: results of the ACABi national survey...

Posted by : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Journal name : Bull Cancer

Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab

AbstractBackground: Trastuzumab is used, alone or in conjunction with standard chemotherapy, to treat HER2-positive...

Posted by : Mr. Antoine FALCOZ, Dr. Dewi VERNEREY
Journal name : Front Cardiovasc Med

Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide-Based Vaccine in Patients With Refractory Advanced Non-Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation Study

AbstractPurpose: Universal cancer peptide-based vaccine (UCPVax) is a therapeutic vaccine composed of two highly...

Posted by : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Journal name : J Clin Oncol

Could 18-FDG PET-CT Radiomic Features Predict the Locoregional Progression-Free Survival in Inoperable or Unresectable Oesophageal Cancer?

AbstractBackground: We evaluated the value of pre-treatment positron-emission tomography-computed tomography...

Posted by : Mme. Julie HENRIQUES, Mr. Antoine FALCOZ, Dr. Dewi VERNEREY
Journal name : Cancers (Basel)

Correlation between efficacy endpoints in patients with advanced biliary tract cancer treated by systemic second-line therapies: Analysis of aggregated data from a systematic literature review

AbstractBackground: Overall response rate (ORR) and progression-free survival (PFS) are commonly used as endpoints...

Posted by : Dr. Dewi VERNEREY
Journal name : Clin Res Hepatol Gastroenterol

Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study

AbstractPurpose: In patients with resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma, surgery plus...

Posted by : Dr. Dewi VERNEREY, Mme. Julie HENRIQUES
Journal name : Journal of Clinical Oncology

A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 T H 1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study

AbstractBackground: There is a strong rational of using anti-programmed cell death protein-1 and its ligand...

Posted by : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Journal name : Front Oncol

Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study"

AbstractIntroduction: Regorafenib (R) and trifluridine/tipiracil (FTD/TPI) are of proven efficacy in metastatic...

Posted by : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Journal name : Clinical colorectal cancer

Impact of trough concentrations of regorafenib and its major metabolites M-2 and M-5 on overall survival of chemorefractory metastatic colorectal cancer patients: Results from a multicentre GERCOR TEXCAN phase II study

AbstractPurpose: This prospective pharmacokinetic (PK) ancillary study of the TEXCAN phase II GERCOR trial of...

Posted by : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Journal name : European journal of cancer

Early Post-Transplant Red Blood Cell Transfusion Is Associated With an Increased Risk of Transplant Failure: A Nationwide French Study

AbstractBackground: Red blood cell (RBC) transfusions are frequently required in the early period after kidney...

Posted by : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Journal name : Frontiers in oncology

Prognostic value of CD4+ T lymphopenia in non-small cell lung Cancer

AbstractBackground: There is a paucity of data regarding the prognostic influence of peripheral blood CD4+ T...

Posted by : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Journal name : BMC cancer

Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR)

AbstractBackground: Histological characteristics at the invasive front may reflect tumor aggressiveness;...

Posted by : Mr. Antoine FALCOZ, Dr. Dewi VERNEREY
Journal name : Annals of oncology

Result of one-year, prospective follow-up of intensive care unit survivors after SARS-CoV-2 pneumonia

AbstractIntroduction: Survivors of viral ARDS are at risk of long-term physical, functional and neuropsychological...

Posted by : Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY, Dr. Sophie PAGET-BAILLY
Journal name : Annals of Intensive Care

Interest of the Addition of Taxanes to Standard Treatment in First-Line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients

AbstractBackground: Studies have reported a beneficial role of the addition of trastuzumab to platin-5-FU based...

Posted by : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Journal name : Frontiers in oncology

Is it safe to perform an anastomosis for rectal cancer after prostate cancer? A multicentre study of 126 patients from the GRECCAR group

AbstractAim: To determine the safety of performing an anastomosis after rectal cancer (RC) resection in patients...

Posted by : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Journal name : Colorectal Dis

Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies

AbstractBackground: Squamous cell carcinoma of the anus (SCCA) is a rare disease often diagnosed at a localised...

Posted by : Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Journal name : Eur J Cancer

Immune microenvironment in patients with mismatch-repair-proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study

AbstractIn the era of immune checkpoint inhibitors, understanding the metastatic microenvironment of proficient mismatch...

Posted by : Dr. Dewi VERNEREY
Journal name : Mol Oncol

Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin

AbstractPurpose: Early-onset (EO) colorectal cancer (CRC, age < 50 years) incidence is increasing. Decisions on...

Posted by : Dr. Dewi VERNEREY
Journal name : J Clin Oncol

Impact of Immunoscore on the Management of Stage II Colon Cancer Patients: A Physician Survey

AbstractBackground: Adjuvant chemotherapy use in stage II colon cancer is controversial. Current prognostic risk...

Posted by : Dr. Dewi VERNEREY
Journal name : Cancers (Basel)

HPV16 Load Is a Potential Biomarker to Predict Risk of High-Grade Cervical Lesions in High-Risk HPV-Infected Women: A Large Longitudinal French Hospital-Based Cohort Study

AbstractHigh-risk HPV (hrHPV) testing has been implemented as a primary screening tool for cervical cancer in numerous...

Posted by : Mme. Julie HENRIQUES, Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY, Dr. Sophie PAGET-BAILLY
Journal name : Cancers (Basel)

Metastatic colorectal carcinoma with signet-ring cells: Clinical, histological and molecular description from an Association des Gastro-Entérologues Oncologues (AGEO) French multicenter retrospective cohort

AbstractBackground: Metastatic signet-ring cell colorectal carcinoma is rare. We analyzed its clinicopathological...

Posted by : , Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Journal name : Dig Liver Dis

Prognostic value and relation with adjuvant treatment duration of ctDNA in stage III colon cancer: a post-hoc analysis of the PRODIGE-GERCOR IDEA-France trial

AbstractPurpose: Circulating tumor DNA (ctDNA) has been suggested as a major prognostic factor in resected stage...

Posted by : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Journal name : Clin Cancer Res .

Additive Value of Preoperative Sarcopenia and Lymphopenia for Prognosis Prediction in Localized Pancreatic Ductal Adenocarcinoma

AbstractBackground: Surgical resection with adjuvant chemotherapy is the only treatment that can provide long term...

Posted by : Dr. Dewi VERNEREY, ,
Journal name : Front Oncol

Monitoring levels of circulating cell-free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment

AbstractCirculating cell-free DNA (cfDNA) contains circulating tumor DNA (ctDNA), which can be obtained from serial...

Posted by : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Journal name : Mol Oncol .

Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study

AbstractBackground: The Immunoscore (IS), which prognostically classifies stage I-III colon cancer (CC) patients,...

Posted by : Dr. Dewi VERNEREY, Mme. Julie HENRIQUES
Journal name : Ann Oncol

Investigation of Relation of Radiation Therapy Quality With Toxicity and Survival in LAP07 Phase 3 Trial for Locally Advanced Pancreatic Carcinoma

AbstractKeywords: RTQA; chemoradiotherapy; locally advanced; pancreatic adenocarcinoma; quality control; radiation...

Posted by : Dr. Dewi VERNEREY
Journal name : Int J Radiat Oncol Biol Phys

Predictive Value of Neutrophils Count for Local Tumor Control After Chemoradiotherapy in Patients With Locally Advanced Pancreatic Carcinoma

AbstractPurpose: Baseline neutrophil count may predict overall survival (OS) in patients with locally advanced...

Posted by : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Journal name : Int J Radiat Oncol Biol Phys

Panel gene profiling of small bowel adenocarcinoma: Results from the NADEGE prospective cohort

AbstractSmall bowel adenocarcinoma (SBA) is a rare tumour. Large genomic analyses with prognostic assessments are...

Posted by : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Journal name : Int J Cancer

Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma

AbstractAims: The addition of docetaxel to cisplatin and 5-fluorouracil (DCF) has shown promising efficacy in...

Posted by : Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Journal name : Ther Adv Med Oncol

Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial

AbstractBackground: The IMMUNOBIL PRODIGE 57 trial is a non-comparative randomized phase II study assessing the...

Posted by : Dr. Dewi VERNEREY
Journal name : Eur J Cancer

Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer

AbstractFluoropyrimidine (FP) plus platinum chemotherapy has been recently established as a second-line (L2) preferred...

Posted by : , Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Journal name : Int J Cancer

Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials

AbstractBackground: A prospective, pooled analysis of six randomised phase 3 trials was done to investigate...

Posted by : Dr. Dewi VERNEREY
Journal name : Lancet Oncol

How to Choose the Right Treatment for Patients With Advanced Squamous Cell Carcinoma in the Absence of a Comparative Randomized Clinical Trial

In their recent article in Journal of Clinical Oncology regarding the InterAAct phase II trial in advanced...

Posted by : Dr. Dewi VERNEREY
Journal name : J Clin Oncol

11 2020, November

Quality of patient-reported outcome reporting according to the CONSORT statement in randomized controlled trials with glioblastoma patients

AbstractBackground: Randomized controlled trials (RCTs) represent the best evidence in oncology research....

Posted by : Mr. Antoine FALCOZ, Dr. Sophie PAGET-BAILLY, Dr. Dewi VERNEREY
Journal name : Neurooncol Pract

RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study

AbstractBackground: Immune checkpoint inhibitors (ICIs) are highly effective in patients with microsatellite...

Posted by : Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Journal name : J Immunother Cancer

Small bowel adenocarcinoma: Results from a nationwide prospective ARCAD-NADEGE cohort study of 347 patients

AbstractSmall bowel adenocarcinoma (SBA) is a rare tumour. We conducted a prospective cohort to describe the prevalence,...

Posted by : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Journal name : Int J Cancer

Prognostic value of the early change in neutrophil-to-lymphocyte ratio in metastatic pancreatic adenocarcinoma

AbstractIn metastatic pancreatic adenocarcinoma, a high neutrophil-to-lymphocyte ratio (NLR) at diagnosis is a marker of...

Posted by : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Journal name : Clin Res Hepatol Gastroenterol

FOLFIRINOX De‐Escalation in Advanced Pancreatic Cancer: A Multicenter Real‐Life Study

AbstractBackground: Our study describes the feasibility and efficacy of a first-line FOLFIRINOX (5-fluorouracil...

Posted by : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Journal name : Oncologist

Anti-Telomerase CD4 + Th1 Immunity and Monocytic-Myeloid-Derived-Suppressor Cells Are Associated with Long-Term Efficacy Achieved by Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) in Advanced Anal Squamous Cell Carcinoma: Translational Study of Epitopes-HPV01 and 02 Trials

AbstractDocetaxel, cisplatin and 5-fluorouracil (DCF) chemotherapy regimen is highly effective in advanced anal squamous...

Posted by : , Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Journal name : Int J Mol Sci

Exposure-response analysis of Raltitrexed assessing liver toxicity

AbstractAim: Raltitrexed (RTX) is a thymidylate synthase inhibitor with large pharmacokinetics (PK) variability...

Posted by : Dr. Dewi VERNEREY, Mme. Julie HENRIQUES
Journal name : Br J Clin Pharmacol

Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study

AbstractMismatch repair-deficient (dMMR) and/or microsatellite instability-high (MSI) colorectal cancers (CRC) represent...

Posted by : Dr. Dewi VERNEREY, Mme. Julie HENRIQUES
Journal name : Int J Cancer

Surgical Management and Outcomes of Rectal Cancer with Synchronous Prostate Cancer: A Multicenter Experience from the GRECCAR Group

AbstractBackground: Synchronous prostate cancer (PC) and rectal cancer (RC) is a rare clinical situation. While...

Posted by : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Journal name : Ann Surg Oncol

Activity and tolerability of maintenance avelumab immunotherapy after first line polychemotherapy including platinum in patients with locally advanced or metastatic squamous cell penile carcinoma: PULSE

AbstractBackground Metastatic Squamous cell Penile Carcinoma (mSCPC) is an orphan disease with a virally induced...

Posted by : , Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Journal name : Bull Cancer

NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial)

AbstractBackground: Preoperative radiochemotherapy (RCT) is recommended in France prior to total mesorectal...

Posted by : Dr. Dewi VERNEREY
Journal name : BMC Cancer

Prognostic Value of Tumor Deposits for Disease-Free Survival in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the IDEA France Phase III Trial (PRODIGE-GERCOR)

AbstractPatients and methods: A post hoc analysis of all pathologic reports from patients with stage III CC...

Posted by : Mme. Julie HENRIQUES, Mr. Antoine FALCOZ, Dr. Dewi VERNEREY
Journal name : J Clin Oncol

Efficacy of anti-EGFR in MSI metastatic colorectal cancer depending on sporadic or familial origin

AbstractAnti-EGFR efficacy in patients with microsatellite instability (MSI) metastatic colorectal cancer (mCRC)...

Posted by : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Journal name : J Natl Cancer Inst

Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial

AbstractBackground: Modified docetaxel, cisplatin, and 5-fluorouracil (mDCF) regimen has become a new standard for the...

Posted by : Dr. Dewi VERNEREY
Journal name : BMC Cancer

FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study

AbstractBackground: FOLFIRINOX regimen is the first-line reference chemotherapy (L1) in advanced pancreatic ductal...

Posted by : , Dr. Dewi VERNEREY
Journal name : World J Gastrointest Oncol

Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative

AbstractKeywords: Adjuvant; Chemotherapy; Colon cancer; Guidelines; Randomised controlled trials; Time-to-event...

Posted by : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE, Mme. Julie HENRIQUES
Journal name : Eur J Cancer

01 2020, March

Fong's Score in the Era of Modern Perioperative Chemotherapy for Metastatic Colorectal Cancer: A Post Hoc Analysis of the GERCOR-MIROX Phase III Trial

AbstractBackground: Despite improvement in colorectal liver metastasis (CLM) treatment, survival after liver...

Posted by : Dr. Dewi VERNEREY
Journal name : Ann Surg Oncol

Efficacy and Safety of Aflibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter Study

AbstractBackground: Although no data have been reported beyond second-line therapy, aflibercept is approved in this...

Posted by : Dr. Dewi VERNEREY
Journal name : Clin Colorectal Cancer

[Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment]

AbstractIntroduction: Perioperative chemotherapy is the standard strategy for localized gastric cancers....

Posted by : Dr. Dewi VERNEREY
Journal name : Bull Cancer

Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study)

AbstractBackground: Patients with RAS wild-type (WT) nonresectable metastatic colorectal cancer (mCRC) may receive...

Posted by : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Journal name : Oncologist

Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group

AbstractBackground: The bevacizumab-Avastin® adjuVANT (AVANT) study did not meet its primary end point of...

Posted by : Dr. Dewi VERNEREY
Journal name : Ann Oncol .

Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan

AbstractBackground: FOLFIRINOX (leucovorin, 5-fluorouracil, irinotecan, and oxaliplatin) is an option for fit...

Posted by : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Journal name : Clin Colorectal Cancer

Influence of Molecular Status on Recurrence Site in Patients Treated for a Stage III Colon Cancer: a Post Hoc Analysis of the PETACC-8 Trial.

AbstractBACKGROUND:Recurrence patterns in stage III colon cancer (CC) patients according to molecular markers remain...

Posted by : Dr. Dewi VERNEREY,
Journal name : Ann Surg Oncol.

Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial.

AbstractBACKGROUND:Adjuvant treatment for stage II colon cancer (CC) can be proposed to patients with high-risk disease....

Posted by : Dr. Dewi VERNEREY
Journal name : Br J Cancer

Distinct prognostic value of circulating anti-telomerase CD4+ Th1 immunity and exhausted PD-1+/TIM-3+ T cells in lung cancer.

AbstractBACKGROUND:Despite the critical roles of Th1-polarised CD4+ T cells in cancer immunosurveillance, the...

Posted by : Dr. Dewi VERNEREY
Journal name : Br J Cancer.

Mismatch Repair System Deficiency Is Associated With Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer.

AbstractPURPOSE:Defective mismatch repair system (dMMR) has been shown to have a favorable impact on outcome in patients...

Posted by : Dr. Dewi VERNEREY
Journal name : Int J Radiat Oncol Biol Phys

Carcinoembryonic Antigen Levels and Survival in Stage III Colon Cancer: Post hoc Analysis of the MOSAIC and PETACC-8 Trials.

AbstractBACKGROUND:We explored and validated the association of postoperative carcinoembryonic antigen (CEA) with...

Posted by : Dr. Dewi VERNEREY
Journal name : Cancer Epidemiol Biomarkers Prev

BRAF Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGEO RASANC Study.

AbstractIn patients with metastatic colorectal cancer (mCRC), RAS and BRAF mutations are currently determined by tumor...

Posted by : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Journal name : Cancers

Morbidity and oncological outcomes of rectal cancer impaired by previous prostate malignancy.

AbstractBACKGROUND:Specific surgical and oncological outcomes in patients with rectal cancer surgery after a previous...

Posted by : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Journal name : Br J Surg

A GERCOR-AERIO national survey of oncology residents in France: Current setting and expectations regarding post-internship and research.

AbstractINTRODUCTION:The demographics of oncology residents has changed since 2010 with the increase in the size of...

Posted by : Dr. Dewi VERNEREY
Journal name : Bull Cancer

PRODIG (Prevention of new onset diabetes after transplantation by a short term treatment of Vildagliptin in the early renal post-transplant period) study: study protocol for a randomized controlled study.

AbstractBACKGROUND:Post-transplant diabetes is a frequent and serious complication of kidney transplantation. There is...

Posted by : Dr. Dewi VERNEREY
Journal name : Trials

Peritoneal dialysis after kidney transplant failure: a nationwide matched cohort study from the French Language Peritoneal Dialysis Registry (RDPLF)

AbstractBackground: Failed kidney transplant is becoming a frequent cause of dialysis initiation. Although studies...

Posted by : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Journal name : Nephrol Dial Transplant

Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations.

AbstractBACKGROUND:The benefit of second-line chemotherapy (L2) over standard first-line (L1) gemcitabine plus cisplatin...

Posted by : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Journal name : Eur J Cancer.

Appropriateness of pancreatic resection in high-risk individuals for familial pancreatic ductal adenocarcinoma: a patient-level meta-analysis and proposition of the Beaujon score.

AbstractBACKGROUND:About 5% of pancreatic ductal adenocarcinomas are inherited due to a deleterious germline mutation...

Posted by : Dr. Dewi VERNEREY
Journal name : United European Gastroenterol

Health-related quality of life assessment for patients with advanced or metastatic renal cell carcinoma treated with a tyrosine kinase inhibitor using electronic patient-reported outcomes in daily clinical practice (QUANARIE trial): study protocol.

ABSTRACTBACKGROUND: Two main therapies, pazopanib and sunitinib, are used in the first-line setting for metastatic renal...

Posted by : , Mme. Joëlle FRITZSCH, Dr. Sophie PAGET-BAILLY, , Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Journal name : Health and Quality of Life Outcomes

Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.

AbstractBACKGROUND:The incidence of anal squamous cell carcinoma has been increasing markedly in the past few decades....

Posted by : Pr. Franck BONNETAIN, Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Journal name : Lancet Oncol

Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study).

AbstractBACKGROUND:At time of diagnosis, less than 10% of patients with pancreatic adenocarcinomas (PDAC) are considered...

Posted by : Dr. Dewi VERNEREY
Journal name : BMC Cancer

Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.

AbstractBACKGROUND:The incidence of anal squamous cell carcinoma has been increasing markedly in the past few decades....

Posted by : Pr. Franck BONNETAIN, Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Journal name : Lancet Oncol

Low-level postoperative carcinoembryonic antigen improves survival outcomes stratification in patients with stage II colon cancer treated with standard adjuvant treatments.

Letter to editor.LINK

Posted by : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY
Journal name : European Journal of Cancer

Open-label, randomized multicentre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma: study protocol of the SURF trial

ABSTRACTBackgroundSunitinib is a tyrosine kinase inhibitor approved in the first-line metastatic renal cell carcinoma...

Posted by : , Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Journal name : Trials

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.

BACKGROUND:Since 2004, a regimen of 6 months of treatment with oxaliplatin plus a fluoropyrimidine has been standard...

Posted by : Dr. Dewi VERNEREY
Journal name : New England Journal of Medicine

3 Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial

ABSTRACTPurpose Reduction of adjuvant treatment duration may decrease toxicities without loss of efficacy in stage III...

Posted by : Dr. Dewi VERNEREY, Dr. Sophie PAGET-BAILLY, Pr. Franck BONNETAIN
Journal name : Journal of Clinical Oncology

RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study.

BACKGROUND:RAS mutations are currently sought for in tumor samples, which takes a median of almost 3 weeks in western...

Posted by : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN, Mme. Aurélia MEURISSE
Journal name : Ann Oncol

Potential added value of a RT-qPCR method of SOX 11 expression, in the context of a multidisciplinary diagnostic assessment of B cell malignancies.

BACKGROUND:Expression of SRY [sex-determining region Y]-box11 (SOX11) is specific to mantle cell lymphoma (MCL) and...

Posted by : Dr. Dewi VERNEREY
Journal name : Exp Hematol Oncol

Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.

BackgroundPatients treated with chemotherapy for microsatellite unstable (MSI) and/or mismatch repair deficient (dMMR)...

Posted by : Dr. Dewi VERNEREY
Journal name : Eur J Cancer

A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study

Abstract Background The overexpression of human epidermal growth factor receptor-2 (HER2) in breast cancer is a...

Posted by : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY
Journal name : BMC Cancer

Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy

Since the MOSAIC study, oxaliplatin-based adjuvant chemotherapy has been the standard treatment of stage III colon...

Posted by : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Journal name : Annals of Oncology

Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma

Background: In advanced pancreatic ductal adenocarcinoma (aPDAC), there is no consensual strategy for second-line...

Posted by : , Dr. Dewi VERNEREY, Pr. Franck BONNETAIN, Mme. Aurélia MEURISSE
Journal name : JNCI J Natl Cancer Inst

Development and validation of the FRAGIRE tool for assessment an older person’s risk for frailty

AbstractBackground:Frailty is highly prevalent in elderly people. While significant progress has been made to...

Posted by : Dr. Dewi VERNEREY, Dr. Sophie PAGET-BAILLY, , Pr. Franck BONNETAIN
Journal name : BMC Geriatrics

Additive value of pre-operative and one-month post-operative lymphocyte count for death-risk stratification in patients with resectable pancreatic cancer: a multicentric study

AbstractBackground:Pancreatic adenocarcinoma (PDAC) incidence is increasing worldwide. Several studies have shown...

Posted by : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Journal name : BMC Cancer

MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors

AbstractTemozolomide (TEM) showed encouraging results in well-differentiated pancreatic neuroendocrine tumors (WDPNETs)....

Posted by : Dr. Dewi VERNEREY
Journal name : Endocrine-Related Cancer

Value of Donor–Specific Anti–HLA Antibody Monitoring and Characterization for Risk Stratification of Kidney Allograft Loss

AbstractThe diagnosis system for allograft loss lacks accurate individual risk stratification on the basis of...

Posted by : Dr. Dewi VERNEREY
Journal name : J Am Soc Nephrol

Prognostic value of baseline seric Syndecan-1 in initially unresectable metastatic colorectal cancer patients: a simple biological score

In first-line metastatic colorectal cancer (mCRC), baseline prognostic factors allowing death risk and treatment...

Posted by : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Journal name : International Journal of Cancer

Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP)

Background:The management of locally advanced pancreatic cancer (LAPC) patients remains controversial. Better...

Posted by : Dr. Dewi VERNEREY, , Pr. Franck BONNETAIN
Journal name : British Journal of Cancer

Prognostic value of health-related quality of life for death risk stratification in patients with unresectable glioblastoma

AbstractGlioblastoma is the most common malignant brain tumor in adults. Baselinehealth-relatedquality of life (HRQoL)...

Posted by : , Dr. Dewi VERNEREY, , Pr. Franck BONNETAIN
Journal name : Cancer Medicine

Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study.

Background: Deficient mismatch repair (dMMR) colon cancer (CC) is reportedly resistant to 5-fluorouracil (5FU) adjuvant...

Posted by : , Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Journal name : JNCI Journal of the National Cancer Institure

Prognostic value of health-related quality of life for overall survival in elderly non-small-cell lung cancer patients

AbstractBACKGROUND:We investigated whether the health-related quality of life (HRQoL) score is a prognostic factor for...

Posted by : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY
Journal name : EJC

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.

AbstractPURPOSE:The MOSAIC (Multicenter International Study of Oxaliplatin/Fluorouracil/Leucovorin in the Adjuvant...

Posted by : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Journal name : JCO

Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial.

AbstractBACKGROUND:The combination of an anti-VEGF or an anti-EGFR-targeted monoclonal antibody with chemotherapy has...

Posted by : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Journal name : Lancet Oncol

Long term outcomes of transplantation using kidneys from expanded criteria donors: prospective, population based cohort study.

AbstractOBJECTIVES:To assess the long term outcomes of transplantation using expanded criteria donors (ECD; donors aged...

Posted by : Dr. Dewi VERNEREY
Journal name : BMJ

Determinants and Outcomes of Accelerated Arteriosclerosis: Major Impact of Circulating Antibodies

ABSTRACT Rationale:The role of circulating antibodies in addition to traditional cardiovascular risk factors in...

Posted by : Dr. Dewi VERNEREY
Journal name : Test

Coexpression of androgen receptor and FOXA1 in nonmetastatic triple-negative breast cancer: ancillary study from PACS08 trial.

AbstractAIM:Microarray studies identified a subgroup of molecular apocrine tumors (estrogen receptor [ER]...

Posted by : Dr. Dewi VERNEREY
Journal name : Future Oncol

Prognostic value of angiopoietin-2 for death risk stratification in patients with metastatic colorectal carcinoma.

Abstract Background: Baseline prognostic biomarkers stratifying treatment strategies in first-line metastatic...

Posted by : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY
Journal name :

Health-related quality-of-life as co-primary endpoint in randomized clinical trials in oncology.

AbstractOverall survival (OS) has been considered as the most relevant primary endpoint but trials using OS often...

Posted by : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY, Dr. Sophie PAGET-BAILLY
Journal name : Expert Review of Anticancer Therapy

 Archives

 Contributor